{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.55","upperLimit":"7.29","value":"5.37"},{"groupId":"OG001","lowerLimit":"0.79","upperLimit":"1.94","value":"1.77"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"The time from the first dose of study treatment to the date of documented disease progression (per RECIST 1.1), or death from any cause","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with advanced or metastatic biliary tract cancer with HER2 amplification by in situ hybridization (ISH) and HER2 overexpression by immunohistochemistry (IHC) which includes IHC 2+ or 3+","id":"OG000","title":"Cohort I"},{"description":"Participants with advanced or metastatic biliary tract cancer with HER2 amplification by ISH and HER2 IHC 0 or 1+.","id":"OG001","title":"Cohort II"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 45 months","title":"PFS by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"months"}